Loading
A phase 1/2 trial of Trastuzumab pamirtecan and PM8002 in advanced solid tumours, run by BioNTech SE, now recruiting.
A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer is a phase 1/2 interventional study registered as NCT06827236 by BioNTech SE, with 380 participants planned, started 2025-04-23 and due to reach its primary completion in 2029-08. Interventions recorded: BNT323 and BNT327.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Trastuzumab pamirtecan, Duality Biotherapeutics, BioNTech, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Duality Biotherapeutics, PM8002, BioNTech, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares PM8002, BioNTech, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares PM8002, BioNTech, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares PM8002, BioNTech, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Duality Biotherapeutics, PM8002, BioNTech, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Duality Biotherapeutics, PM8002, BioNTech, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Duality Biotherapeutics, BioNTech, Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/